It’s not exactly mincing words to refer to a federal agency administering a major national program as a “department of dunces.”
We know at Caffery, Oubre, Campbell & Garrison in Lafayette that health care fraud not only exists in Louisiana and across the United States, but runs rampant.
A recent Forbes article on a distinct challenge to insurers from the medical realm underscores that the industry “is susceptible to a range of fraud that can cause financial harm and drive up costs in the system.”
Insurance fraud is sometimes relatively confined.
Talk about differing interpretations.
America’s insurance industry is currently riveted on the details of an interesting court case from Washington State. That matter centrally spotlights the extension of personal liability in bad-faith litigation.
It immediately makes sense why drug manufacturers would seek coverage from insurers against claims that opioid-linked addictions and resulting harms spiked following their alleged downplaying of known drug risks for users.
The age-old American maxim “turnabout is fair play” conveys a fairly simple idea, namely this: If you get the chance to do something, fairness dictates that I receive the same opportunity.
An individual unfamiliar with the term “legacy lawsuit” might reasonably think it is litigation filed by the estate of a well-known decedent whose reputation or life’s work has somehow been tarnished by third parties.
As a long-tenured and proven Louisiana insurance defense law firm, the attorneys at Caffery, Oubre, Campbell & Garrison have represented diverse businesses and insurers across a wide universe of industry-linked matters.